Found 20 clinical trials
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested
- 15 views
- 07 Aug, 2021
- 31 locations
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, …
- 308 views
- 17 Sep, 2021
- 81 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
HR+/HER2-negative BC represent 70% of all newly diagnosed breast tumours and are responsible for most recurrences and deaths due to this disease, and despite available standard therapies, 15-20% of hormone tumours recur at distant sites. As BC is a clinically and biologically heterogeneous disease, intrincsic subtype may play an important …
- 0 views
- 02 Aug, 2021
- 15 locations
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic
- 0 views
- 08 Apr, 2021
- 1 location
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …
- 13 views
- 25 Jul, 2021
- 12 locations
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III clinical trial.
- 7 views
- 22 Jan, 2021
- 1 location
A Study of BDTX-189 an Orally Available Allosteric ErbB Inhibitor in Patients With Advanced Solid Tumors.
2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to: Find the recommended dose of BDTX-189 that can be given safely to
- 3 views
- 07 Aug, 2021
- 25 locations
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with EGFR or HER2 exon 20 mutation that is stage IV or has come back. Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- 1904 views
- 16 Sep, 2021
- 2 locations
Assessing the Immunogenicity of pING-hHER3FL
receptor (HER) family including: HER1 (also known as EGFR), HER2, HER3 and HER4 (also known as ErbB2, ErbB3, and ErbB4 respectively) is an important receptor family for the development of many malignancies
- 0 views
- 24 Jan, 2021
- 1 location
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
> Tumor positive for Epstein-Barr virus (EBV) (8%), which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, ErbB2, PD-L1 and PD-L2;
- 0 views
- 06 Apr, 2021
- 8 locations
- 1
- 2